Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Large Growth in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totaling 7,378,003 shares, a growth of 20.2% from the December 31st total of 6,136,786 shares. Based on an average daily trading volume, of 848,791 shares, the short-interest ratio is currently 8.7 days. Currently, 20.6% of the shares of the stock are sold short. Currently, 20.6% of the shares of the stock are sold short. Based on an average daily trading volume, of 848,791 shares, the short-interest ratio is currently 8.7 days.

Wall Street Analyst Weigh In

Several research firms have commented on DNTH. Jefferies Financial Group boosted their price objective on Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a research note on Monday. Wedbush reaffirmed an “outperform” rating and issued a $46.00 price target on shares of Dianthus Therapeutics in a research note on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Truist Financial lifted their target price on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Finally, HC Wainwright upped their target price on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $66.50.

Insiders Place Their Bets

In related news, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Simrat Randhawa sold 109,031 shares of the stock in a transaction on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the transaction, the executive vice president directly owned 4,000 shares in the company, valued at approximately $152,560. The trade was a 96.46% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 216,538 shares of company stock worth $8,283,175 in the last three months. 8.15% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock valued at $280,000 after buying an additional 618 shares during the period. AlphaQuest LLC purchased a new position in Dianthus Therapeutics in the second quarter worth approximately $94,000. Ensign Peak Advisors Inc acquired a new stake in Dianthus Therapeutics during the second quarter worth $2,504,000. American Century Companies Inc. increased its stake in Dianthus Therapeutics by 13.2% during the second quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock worth $1,009,000 after acquiring an additional 6,323 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Dianthus Therapeutics in the second quarter valued at $503,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Performance

NASDAQ DNTH opened at $48.13 on Thursday. The stock’s fifty day moving average is $44.23 and its two-hundred day moving average is $35.79. The firm has a market capitalization of $2.08 billion, a P/E ratio of -13.83 and a beta of 1.59. Dianthus Therapeutics has a fifty-two week low of $13.36 and a fifty-two week high of $57.50.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.11). The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.58 million. Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%. As a group, sell-side analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.